A real-world retrospective study has shown that patients experiencing progressive daily vision loss from geographic atrophy (GA), a late form of nonexudative age-related macular degeneration, may derive the most benefit from the complement inhibitor pegcetacoplan, which the US Food and Drug Administration (FDA) last year approved as the first treatment for the condition. …
